<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474354</url>
  </required_header>
  <id_info>
    <org_study_id>IIS_Malagari Athens_BTG</org_study_id>
    <nct_id>NCT03474354</nct_id>
  </id_info>
  <brief_title>DC Bead LUMI (TM) Loaded With Doxorubicin for Intermediate Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Correlation of Necrosis With DC Bead LUMI (TM) Distribution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Malagari Katerina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Athens</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to evaluate the distribution of radiopaque microspheres&#xD;
      loaded with doxorubicin in the treatment of unresectable HCC. Prospective, single arm, open&#xD;
      label, single centre, pilot study. All patients will undergo clinical follow-up. Twenty&#xD;
      patients will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of the study is to evaluate the distribution of radiopaque microspheres&#xD;
      loaded with doxorubicin in the treatment of unresectable HCC. Prospective, single arm, open&#xD;
      label, single centre, pilot study. All patients will undergo clinical follow-up. Twenty&#xD;
      patients will be enrolled. Primary endpoint : Local response (evaluated with CT and MRI at 4&#xD;
      to 6 weeks post each procedure and at 6 months according to mRECIST) in patients with&#xD;
      intermediate-stage HCC following chemoembolisation with radiopaque bead. Secondary endpoints&#xD;
      include: 1) Better definition of end point of embolization for drug eluting beads : Ability&#xD;
      to achieve near-stasis during chemoembolisation procedure in the tumour feeding vessels using&#xD;
      intra-procedural imaging feedback from the radiopaque bead (early visualization of non target&#xD;
      embolization 2) Total dose needed for tumor devascularization 3)Distribution of radiopaque&#xD;
      beads and correlation with necrosis and adverse events&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">April 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CORRELATION OF LUMI DISTRIBUTION WITH NECROSIS</measure>
    <time_frame>12 months</time_frame>
    <description>Local response following chemoembolisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Definition of end point of embolization for drug eluting beads</measure>
    <time_frame>12 months</time_frame>
    <description>optimization of embolization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose needed for tumor devascularization</measure>
    <time_frame>12 months</time_frame>
    <description>dose required for tumor devascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of radiopaque beads and correlation with necrosis</measure>
    <time_frame>12 months</time_frame>
    <description>correlation between imaging and tumor necrosis</description>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Cancer</condition>
  <condition>Chemoembolization</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>chemoembolization</intervention_name>
    <description>correlation of necrosis with the deposition of beads</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with intermediate stage hepatocellular carcinoma (BCLC B)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is at least 18 years old.&#xD;
&#xD;
          2. HCC diagnosed according to updated American Association for the Study of Liver&#xD;
             Diseases (AASLD) criteria.&#xD;
&#xD;
          3. Barcelona Criteria Liver Cancer (BCLC) stage B patients or BCLC stage A patients not&#xD;
             candidates for curative treatment (resection, transplantation, ablation) or who have&#xD;
             failed/recurred after resection/ablation).&#xD;
&#xD;
          4. Tumour burden (located in one or two lobes) that can be sufficiently and selectively&#xD;
             embolised with required dose or radiopaque bead loaded with doxorubicin.&#xD;
&#xD;
          5. Performance status: Eastern Cooperative Oncology Group (ECOG) status 0/1.&#xD;
&#xD;
          6. Normal liver or compensated cirrhosis with preserved liver function (Child-Pugh A&#xD;
             score and Child/Pugh B≤ 7 points ) without ascites.&#xD;
&#xD;
          7. Total bilirubin ≤2.0 mg/dl.&#xD;
&#xD;
          8. Adequate renal function (serum creatinine &lt; 1.5 X ULN).&#xD;
&#xD;
          9. Patient has provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient previously treated with any intra-arterial therapy for HCC.&#xD;
&#xD;
          2. Eligible for curative treatment (resection/RadioFrequency Ablation-RFA,&#xD;
             transplantation therapies).&#xD;
&#xD;
          3. Advanced liver disease: Child-Pugh's C class or active gastrointestinal bleeding,&#xD;
             encephalopathy. Bilirubin levels &gt;2.0 mg/dl.&#xD;
&#xD;
          4. Advanced tumoural disease: BCLC class C (vascular invasion -even segmental,&#xD;
             extra-hepatic spread or cancer-related symptoms=ECOG of 1-2) or D class (WHO&#xD;
             performance status 3 or 4, Okuda III stage).&#xD;
&#xD;
          5. Patient with another primary tumour.&#xD;
&#xD;
          6. Patient with refractory ascites or on diuretic treatment; minor ascites retention&#xD;
             detected at imaging and not requiring diuretics to be solved is not a&#xD;
             contraindication.&#xD;
&#xD;
          7. Patient with history of biliary tree disease or biliary dilatation.&#xD;
&#xD;
          8. Portal vein thrombosis, porto-systemic shunt, hepatofugal blood flow or absent portal&#xD;
             blood flow in the liver area to be treated.&#xD;
&#xD;
          9. Contraindication to multiphasic CT and MRI (e.g. allergy to contrast media).&#xD;
&#xD;
         10. Any other contraindication for embolisation or local doxorubicin treatment.&#xD;
&#xD;
         11. Patients currently receive treatment with any investigational drug/device/intervention&#xD;
             or have received any investigational product within 1 month or 5 half-lives of the&#xD;
             investigational agent (whichever is longer) before study treatment.&#xD;
&#xD;
         12. In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit&#xD;
             the patient's ability to participate in the study, compliance with follow-up&#xD;
             requirements or impact the scientific integrity of the study.&#xD;
&#xD;
         13. Pregnant or breast-feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>88 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>KATERINA MALAGARI</last_name>
    <role>Principal Investigator</role>
    <affiliation>EVGENIDION HOSPITAL, ATHENS, GREECE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KATERINA MALAGARI, MD</last_name>
    <phone>+30 6977326033</phone>
    <email>kmalag@otenet.gr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HIPPOKRATIS MOSCHOURIS, MD</last_name>
    <phone>+30 6945869966</phone>
    <email>hipmosch@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Evgenidion Hospital</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>15538</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KATERINA MALAGARI, PROFESSOR</last_name>
      <phone>+30 6977 326033</phone>
      <email>kmalag@otenet.gr</email>
    </contact>
    <contact_backup>
      <last_name>THODOROS KIAKIDIS, MD</last_name>
      <phone>+30 210 7227 488</phone>
      <email>thkiakidis@outlook.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ippokratis Moschouris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Athens</investigator_affiliation>
    <investigator_full_name>Malagari Katerina</investigator_full_name>
    <investigator_title>ASSOCIATE PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>chemoembolization</keyword>
  <keyword>drug eluting beads</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>CT and MRI images will be stored anonymously by giving each patient a code number</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>starting February 2018 and ending February 2019</ipd_time_frame>
    <ipd_access_criteria>the principal investigator and collaborator will record and analyse data from the CT and MRI of the patients. The names of the patients will not be in the examinations and identity will be given by enrollment number</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

